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INTRODUCTION
The development of neutralizing anti-factor VIII (FVIII) antibodies is a serious complication that may be encountered when FVIII replacement therapy is administered to hemophilia A (HA) patients, affecting 25-30% of the treated HA population with a peak occurrence following ~14 FVIII infusions [1] [2] [3] .
injected over the sensor in three flow channels, while the fourth channel served as a reference.
BO2C11-Fab was immobilized covalently by amine derivatization. Single-cycle kinetics experiments 15 were carried out in which wild-type or mutant FVIII-C2 proteins were injected serially over the biosensor surfaces at increasing concentrations, without regenerating the biosensor surface after each injection, followed by a 30-60 minute buffer injection to measure dissociation rates. The association (k a in lead optimization studies of potential inhibitory drug targets [16] [17] [18] [19] .
Visualization of B-cell epitopes:
After the SPR data were collected the crystal structures of FVIII-C2 20 and B-domain-deleted FVIII 21, 22 were visualized using the graphics program PyMOL 23 to localize the sites showing altered binding kinetics to the mAbs analyzed herein. The cutoff k d value was chosen empirically, to minimize the number of potential epitope residues located distal from the primary clusters of candidate residues for this series of mAbs.
RESULTS

FVIII-C2 proteins:
WT-FVIII-C2 and 60 FVIII-C2 muteins were purified to >95% homogeneity (Supplemental Figure 1) . Six additional FVIII-C2 muteins (S2193A, K2227A, V2232A, K2236A, K2279A and K2281A) were not expressed in a soluble form and were therefore not analyzed. Dynamic light scattering analyses of the purified proteins, carried out for aliquots of each protein preparation both before and after freezing at -80 o C, showed a single peak at the expected size for monomeric FVIII-C2
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From (not shown). Some of the mutant protein preparations showed evidence of higher molecular weight aggregates; these were not analyzed further and were discarded. Multiple aliquots of each wellbehaved FVIII-C2 protein preparation were stored frozen to avoid multiple freeze-thaw cycles that could endanger protein structural integrity. Representative sensorgrams are shown in Figure 1 . Almost all of the FVIII-C2 muteins showed binding kinetics to some or all of the mAbs that were highly similar to the binding of WT-FVIII-C2 (see summary of results in Table 1 and kinetic constants in Supplemental was judged to be a conformational effect and it was not assigned to the epitope for this mAb. The kinetic data from analyzing several preparations of FVIII-C2-F2200A and FVIII-C2-R2220A were more variable and of poorer quality than that of WT-FVIII-C2 and the other muteins, indicating these substitutions altered the protein stability. Nevertheless, the fact that neighboring residues were also pinpointed as parts of epitopes recognized by type AB and B antibodies supported their assignment to these epitopes. Qualitatively, several other FVIII-C2 muteins showed increased antibody-antigen dissociation rates relative to WT-FVIII-C2 although accurate kinetic constants could not be obtained.
These results are indicated in Table 1 as "QFD" for "Qualitative Fast Dissociation".
Identification of B-cell epitopes:
The residues identified by the cutoff criterion of k d (mutein) > 2.0X k d (WT), when visualized using PyMOL 23 , formed distinct clusters indicating the FVIII-C2 surfaces recognized by each mAb (Figure 2 ). Once a cluster was localized to a specific surface region, the full set of FVIII-C2 muteins was not analyzed by SPR as it was considered sufficient to concentrate on residues adjacent to the initial surface thus identified. Substitutions causing altered kinetics at positions that were conformationally non-contiguous with the SPR-identified clusters of potential B-cell epitope residues are noted below as "outliers". Specific characteristics of the binding interactions in each antibody-antigen complex are described below, with the inhibitory mAbs identified as Type A, AB, B, BC or C according to the criteria of Meeks et al.
13
Type A Inhibitors: Three type A inhibitors (ESH4, 3E6 and I54) were evaluated. SPR assays identified the following residues as possibly interacting with all three of these mAbs: D2187, K2207, H2211, L2212 and Q2213. These three epitopes identified kinetically were similar but not identical.
Experiments with ESH4 also identified residues E2181, T2202, S2206 and R2220 as possibly contributing to this epitope, but R2220 was excluded subsequently as an outlier, as described above.
Experiments with I54 also identified residues E2181 and S2206. These Type A epitopes are
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Type AB Inhibitors: Two type AB inhibitors (I109 and BO2C11) were evaluated. SPR assays identified one cluster of residues as possibly interacting with both of these mAbs: F2196, N2198, F2200 and R2220. I109 also possibly interacted with T2202, S2250, L2251, L2252, T2253, S2254 and H2315, and BO2C11 also possibly interacted with E2181 (outlier), M2199, R2215, Q2270 (outlier) and Q2316. Thus the type AB inhibitors were seen to bind either or both of these hydrophobic beta turns. Modeling of epitopes in the FVIII structure: Figure 3A shows the BC and C epitope residues that comprise "non-classical" inhibitor antibodies, e.g. antibodies that prevent FVIII activation by thrombin and/or FXa. Figure 3B shows the location of the epitopes recognized by Type A, AB, B, BC and C antibodies.
DISCUSSION
The SPR experiments identified three distinct clusters of surface-exposed side chains on FVIII-C2 that contributed significant binding avidity for Type A, B and C FVIII-neutralizing antibodies, plus two clusters containing residues that comprised overlap regions for mAb types AB and BC, respectively. SPR experiments were carried out for three type A and two each of types AB, B, BC and C mAbs. The resulting assignments of epitope residues were consistent within each mAb type and were also consistent with the competition ELISA experiments 13 , with peptide-based epitope mapping of FVIII-C2 26,27 , as well as with ELISA assays evaluating binding of the mAbs to the following FVIII muteins:
F2196L, K2227E, M2199I/F2200L, V2223A/K2227E and M2199I/F2200L/L2251V/L2252F 13 . A recent analysis of antibodies purified from a subject with an autoimmune response to FVIII (acquired hemophilia A), indicated that these included antibodies with epitopes similar to those recognized by ESH4 (Type A) and ESH8 (Type C) 28 . The bleeding phenotype of acquired hemophilia A is often more severe than that of congenital severe hemophilia A, possibly because these antibodies bind to a somewhat different set of immunodominant B-cell epitopes and block FVIII functionality more effectively.
The strategy chosen to identify specific residues as members of a B-cell epitope by SPR was to compare the experimental dissociation rate constant k d for a given FVIII-C2 mutein with the k d for WT-FVIII-C2 dissociating from the same antibody, noting which substitutions increased the k d to >2.0X that 13 , pinpointed specific surfaces on the FVIII protein that interact with its partners in promoting blood coagulation. The lists of residues comprising these epitopes ( Table 1) are not comprehensive, because not all surface residues were mutated, and several substitutions affected protein stability so
were not analyzed further. However, the coverage of the protein surface was sufficient to definitively identify distinct clusters of residues contributing to specific antigen-antibody binding avidities.
The type A, AB and B inhibitors interfere with FVIII or FVIIIa binding to phosphatidylserine-containing phospholipid membranes 13 . As expected, the epitopes recognized by the AB and B mAbs included the hydrophobic beta hairpin turns as well as residues H2315-Q2316, which are known to participate in membrane binding 25, 29 . ELISA experiments reported earlier 13 showed that the epitope recognized by Type AB inhibitor I109 includes residues M2199 and F2200, and the SPR results confirm that this mAb also binds to the second hairpin turn containing L2251 and L2252. Interestingly, the epitopes recognized by the Type A inhibitors ESH4, I54 and 3E6 are poised just above these projecting hairpin turns, and their inclusion of charged residues (E2181, D2187, K2206, K2207) indicates that these inhibitors block electrostatic interactions that could otherwise form between the positively charged FVIII side chains and negatively charged membrane surfaces. comprise part of this epitope. The ESH8 epitope also includes residues H2309 and Q2311, which are distal in the linear amino acid sequence of FVIII but adjacent to the other epitope residues on the protein surface. This surface is on the opposite side of the C2 domain from the Type A epitopes (Figures 2 and 3) . The epitope recognized by the other type C mAb, 2-117, maps to a similar surface on FVIII-C2. Unlike ESH8, however, it includes residues H2269 and Q2270, which are on a loop adjacent to the ESH8 epitope, and R2307. Unlike ESH8, 2-117 is only weakly inhibitory 13 . Possibly its binding to this loop precludes stabilization of the FVIII-vWF complex and/or the facilitated removal of thrombin-cleaved FVIIIa that has been hypothesized for the other Type C inhibitor, ESH8 36 . The substitution R2220A affected binding to type C mAbs 2-117 and ESH8, increasing their k d constants by 3.0X and 4.5X, respectively. R2220 is not conformationally contiguous with the other residues identified by SPR, therefore it was identified as an "outlier" and not included as part of these functional epitopes. The epitopes recognized by Type BC mAbs 2-77 and 3G6 overlap the Type C epitopes but also include N2225 and E2228, which are part of Type B epitopes and are further down the "back" face of FVIII-C2 towards the membrane-binding surface. Type C and BC antibodies inhibit FVIII activation by thrombin and/or FXa, but most of those analyzed to date did not compete effectively for FVIII binding to vWF 13 . These antibodies are considered "non-classical" inhibitors because their identification pointed to a previously under-appreciated and important role for the FVIII-C2 domain in proteolytic activation of FVIII. Their localization at a surface distinct from the other types of epitopes, and also on an outer surface of the FVIII protein (i.e. not at an interdomain interface) is shown in Figures 3A and 3B . alanine substitutions at 20 of these sites were characterized by SPR. The human residues at 14 of these sites were identified as contributing to B-cell epitopes recognized by neutralizing anti-FVIII antibodies ( Figure 3C ). For Table 1   A  A  B  B  B  C  C   E  S  H  4  3  E  6  I  5  4  I  1  0  9  B  O  2  C  1  1  1  B  5  3  D  1  2  3  G  6  2  -7  7  2  -1  1 
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